Evidence map›Paper›PMID 26491546›Full record

ArticleJournal of ophthalmology2015

Inhibition of Corneal Neovascularization by Subconjunctival Injection of Fc-Endostatin, a Novel Inhibitor of Angiogenesis.

Junko Yoshida, Robert T Wicks, Andrea I Zambrano, Betty M Tyler, Kashi Javaherian, Rachel Grossman, Yassine J Daoud, Peter Gehlbach, Henry Brem, Walter J Stark

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ophthalmology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Therapeutic Exosomes CarryingBiomedicines · 2026
    Article
  2. Review
  3. Animal models of ocular angiogenesis: from development to pathologies.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Junko YoshidaWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Robert T WicksDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Andrea I ZambranoWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Betty M TylerDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Kashi JavaherianCenter of Cancer Systems Biology, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA.
Rachel GrossmanDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Yassine J DaoudWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Peter GehlbachWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Henry BremWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA ; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA ; Departments of Oncology and Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Walter J StarkWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Johns Hopkins University · USJohns Hopkins Medicine · USTufts University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We assessed the antiangiogenic effects of subconjunctival injection of Fc-endostatin (FcE) using a human vascular endothelial growth factor-induced rabbit corneal neovascularization model. Angiogenesis was induced in rabbit corneas through intrastromal implantations of VEGF polymer implanted 2 mm from the limbus. NZW rabbits were separated into groups receiving twice weekly subconjunctival injections of either saline; 25 mg/mL bevacizumab; 2 mg/mL FcE; or 20 mg/mL FcE. Corneas were digitally imaged at 5 time points. An angiogenesis index (AI) was calculated (vessel length (mm) × vessel number score) for each observation. All treatment groups showed a significant decrease in the vessel length and AI compared to saline on all observation days (P < 0.001). By day 15, FcE 2 inhibited angiogenesis significantly better than FcE 20 (P < 0.01). There was no significant difference between FcE 2 and BV, although the values trended towards significantly increased inhibition by BV. BV was a significantly better inhibitor than FcE 20 by day 8 (P < 0.01). FcE was safe and significantly inhibited new vessel growth in a rabbit corneal neovascularization model. Lower concentration FcE 2 exhibited better inhibition than FcE 20, consistent with previous FcE studies referencing a biphasic dose-response curve. Additional studies are necessary to further elucidate the efficacy and clinical potential of this novel angiogenesis inhibitor.

Identifiers

PMID26491546
PMCPMC4600943
OpenAlexW1921183973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.